Search research articles
Contact Us
Filters
Showing results (101-110 of 121) with videos related to
Page
of 13
Sort By:
British Journal of Cancer
|
November 5, 2016
Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer
Tomoya Yokota, Ken Kato, Yasuo Hamamoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2013
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial
Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui, et al.
The Lancet. Oncology
|
October 5, 2019
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 24, 2017
Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm
Akira Sawaki, Yasuhide Yamada, Kensei Yamaguchi, et al.
JAMA Network Open
|
August 3, 2019
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
Takaki Yoshikawa, Kei Muro, Kohei Shitara, et al.
Clinical Colorectal Cancer
|
September 3, 2018
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials
Takayuki Yoshino, Kentaro Yamazaki, Eiji Shinozaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2022
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Morihito Okada, Ken Kato, Byoung Chul Cho, et al.
Esophagus : Official Journal of the Japan Esophageal Society
|
November 25, 2025
Feasibility of endoscopic response evaluation after induction chemotherapy for determining treatment strategies in esophageal cancer: a post hoc analysis of the CROC trial
Chikatoshi Katada, Tetsuji Yokoyama, Akinori Watanabe, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 5, 2024
Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial
Chikatoshi Katada, Tetsuji Yokoyama, Akinori Watanabe, et al.
Cancer Science
|
July 6, 2025
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
Akihito Kawazoe, Kensei Yamaguchi, Tetsuya Hamaguchi, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 121) with videos related to
Sort By:
Page
of 13
British Journal of Cancer
|
November 5, 2016
Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer
Tomoya Yokota, Ken Kato, Yasuo Hamamoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2013
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial
Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui, et al.
The Lancet. Oncology
|
October 5, 2019
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 24, 2017
Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm
Akira Sawaki, Yasuhide Yamada, Kensei Yamaguchi, et al.
JAMA Network Open
|
August 3, 2019
Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
Takaki Yoshikawa, Kei Muro, Kohei Shitara, et al.
Clinical Colorectal Cancer
|
September 3, 2018
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials
Takayuki Yoshino, Kentaro Yamazaki, Eiji Shinozaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2022
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Morihito Okada, Ken Kato, Byoung Chul Cho, et al.
Esophagus : Official Journal of the Japan Esophageal Society
|
November 25, 2025
Feasibility of endoscopic response evaluation after induction chemotherapy for determining treatment strategies in esophageal cancer: a post hoc analysis of the CROC trial
Chikatoshi Katada, Tetsuji Yokoyama, Akinori Watanabe, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 5, 2024
Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial
Chikatoshi Katada, Tetsuji Yokoyama, Akinori Watanabe, et al.
Cancer Science
|
July 6, 2025
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
Akihito Kawazoe, Kensei Yamaguchi, Tetsuya Hamaguchi, et al.
Page
of 13